Literature DB >> 1437995

The enantiomers of the valproic acid analogue 2-n-propyl-4-pentynoic acid (4-yn-VPA): asymmetric synthesis and highly stereoselective teratogenicity in mice.

R S Hauck1, H Nau.   

Abstract

The teratogenic activities of R(+)- and S(-)-2-n-propyl-4-pentynoic acid (R and S-4-yn-VPA), the enantiomers of the highly teratogenic valproic acid (VPA) analogues (+/-)-4-yn-VPA, were investigated in mice. The enantiomers were prepared via asymmetric synthesis, each in three steps employing the chiral auxiliaries (4R,5S)-4-methyl-5-phenyl-2-oxazolidinone and S-4-benzyl-2-oxazolidinone. The determination of the absolute configurations and the optical purities is described. R(+)-4-yn-VPA contained 7%, and S(-)-4-yn-VPA 8%, of the respective antipodes. The aqueous solutions of the sodium salts of R- and S-4-yn-VPA were administered as single i.p. injections during early organogenesis in the mouse (day 8 of gestation) using the induction of exencephaly as the teratological end point. Dose/exencephaly curves indicated that S-4-yn-VPA is 7.5 times more teratogenic than its antipode, 1.9 times more teratogenic than (+/-)-4-yn-VPA and 3.9 times more teratogenic than the parent drug VPA. In contrast, the neurotoxicity (maternal toxicity) of the 4-yn-VPA enantiomers was found to be independent of the stereo-chemical configuration and lower than achieved after VPA administration. Due to its low neurotoxicity and highly stereoselective neural tube-inducing activity, S-4-yn-VPA should prove an important tool for the investigation of molecular mechanism of the teratogenic action in this class of compounds; R-4-yn-VPA could act as the negative control in these studies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1437995     DOI: 10.1023/a:1015832411981

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  24 in total

1.  Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse.

Authors:  H Nau
Journal:  Teratology       Date:  1986-02

2.  On the development of alternative antiepileptic drugs. Lack of enantioselectivity of the anticonvulsant activity, in contrast to teratogenicity, of 2-n-propyl-4-pentenoic acid and 2-n-propyl-4-pentynoic acid, analogues of the anticonvulsant drug valproic acid.

Authors:  R S Hauck; H Nau; M M Elmazar
Journal:  Naturwissenschaften       Date:  1991-06

3.  Valproic acid teratogenicity in mice after various administration and phenobarbital-pretreatment regimens: the parent drug and not one of the metabolites assayed is implicated as teratogen.

Authors:  H Nau
Journal:  Fundam Appl Toxicol       Date:  1986-05

4.  Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid.

Authors:  E Jäger-Roman; A Deichl; S Jakob; A M Hartmann; S Koch; D Rating; R Steldinger; H Nau; H Helge
Journal:  J Pediatr       Date:  1986-06       Impact factor: 4.406

5.  Valproic acid and spina bifida.

Authors:  T Bjerkedal; A Czeizel; J Goujard; B Kallen; P Mastroiacova; N Nevin; G Oakley; E Robert
Journal:  Lancet       Date:  1982-11-13       Impact factor: 79.321

6.  Valproic acid-induced neural tube defects: reduction by folinic acid in the mouse.

Authors:  M Trotz; C Wegner; H Nau
Journal:  Life Sci       Date:  1987-07-06       Impact factor: 5.037

7.  [Structural bases of the teratogenic effects of the antiepileptic valproic acid. 2-n-propyl-4-pentenic acid, the first structural analogue with significantly higher teratogenic action than VPA].

Authors:  R S Hauck; H Nau
Journal:  Naturwissenschaften       Date:  1989-11

8.  Asymmetric synthesis and enantioselective teratogenicity of 2-n-propyl-4-pentenoic acid (4-en-VPA), an active metabolite of the anticonvulsant drug, valproic acid.

Authors:  R S Hauck; H Nau
Journal:  Toxicol Lett       Date:  1989-10       Impact factor: 4.372

9.  Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers.

Authors:  H Nau; D Rating; S Koch; I Häuser; H Helge
Journal:  J Pharmacol Exp Ther       Date:  1981-12       Impact factor: 4.030

10.  Asymmetric synthesis and teratogenic activity of (R)- and (S)-2-ethylhexanoic acid, a metabolite of the plasticizer di-(2-ethylhexyl)phthalate.

Authors:  R S Hauck; C Wegner; P Blumtritt; J H Fuhrhop; H Nau
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

View more
  4 in total

1.  The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver.

Authors:  S Eyal; J G Lamb; M Smith-Yockman; B Yagen; E Fibach; Y Altschuler; H S White; M Bialer
Journal:  Br J Pharmacol       Date:  2006-08-07       Impact factor: 8.739

2.  Modulation of synaptic transmission and analysis of neuroprotective effects of valproic Acid and derivates in rat embryonic motoneurons.

Authors:  D Ragancokova; Y Song; H Nau; R Dengler; K Krampfl; S Petri
Journal:  Cell Mol Neurobiol       Date:  2010-04-27       Impact factor: 5.046

3.  Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid.

Authors:  O Spiegelstein; B Yagen; R H Levy; R H Finnell; G D Bennett; M Roeder; V Schurig; M Bialer
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

4.  The embryonic stem cell test as tool to assess structure-dependent teratogenicity: the case of valproic acid.

Authors:  Christian Riebeling; Ralph Pirow; Klaus Becker; Roland Buesen; Daniel Eikel; Johanna Kaltenhäuser; Frauke Meyer; Heinz Nau; Birgitta Slawik; Anke Visan; Jutta Volland; Horst Spielmann; Andreas Luch; Andrea Seiler
Journal:  Toxicol Sci       Date:  2011-01-11       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.